Insights in Gynecologic Oncology
Open Access

This review emphasizes the importance of early detection, multidisciplinary management, and ongoing research to enhance patient outcomes in omental cancer. Omental cancer refers to malignancies that predominantly arise in or metastasize to the omentum, a double layer of peritoneum that extends from the stomach and covers the intestines. While the omentum itself is a site of normal fat tissue and immune activity, it can also serve as a nidus for malignant transformation, often as a result of primary cancers from adjacent organs, most notably those of the gastrointestinal tract [1-5]. The omentum is particularly affected in cases of ovarian and gastric cancers, where tumor cells can shed and migrate into the peritoneal cavity. This migration leads to the formation of peritoneal carcinomatosis, a condition marked by the widespread dissemination of cancer cells across the peritoneal surface, including the omentum. Symptoms of omental cancer often include abdominal pain, bloating, and changes in bowel habits, reflecting the invasive nature of the disease and its impact on surrounding structures.

Diagnosis is frequently delayed due to the nonspecific nature of symptoms and the need for advanced imaging techniques, such as computed tomography (CT) scans, to visualize the extent of the disease. Treatment typically involves a combination of surgical resection, such as omentectomy, and systemic chemotherapy. Despite advances in treatment, the prognosis for patients diagnosed with omental cancer remains poor, largely due to late-stage presentation and the aggressive characteristics of the disease. Research into the biological mechanisms of omental cancer and the development of targeted therapies is ongoing, aiming to improve survival rates and quality of life for affected patients. Understanding the unique pathology and treatment challenges associated with omental cancer is essential for advancing patient care and developing effective management strategies.

Omental cancer is a complex and challenging entity that often complicates the clinical management of patients with abdominal malignancies. The discussion surrounding this condition encompasses several critical aspects, including its pathophysiology, clinical presentation, diagnostic methods, treatment strategies, and emerging research directions. The omentum serves as a site for metastatic spread from primary malignancies, particularly from the ovaries and stomach. Cancer cells can invade the omentum through the peritoneal cavity, leading to the formation of omental tumors. The omentum's rich vascular supply and immune-modulating properties create a microenvironment conducive to tumor growth. Factors such as chronic inflammation and hormonal influences may also play a role in promoting malignancy in the omental tissue.

Discussion

Omental cancer represents a significant clinical challenge due to its association with late-stage disease and poor prognosis. A comprehensive understanding of its pathophysiology, improved diagnostic techniques, and advancements in treatment options are essential for enhancing patient outcomes. As research progresses, it is hoped that new strategies will emerge to better manage this complex condition, ultimately improving survival rates and quality of life for affected patients. The theoretical framework surrounding omental cancer highlights the multifactorial nature of this disease [6]. Understanding the interplay between metastatic pathways, the microenvironment, chronic inflammation, genomic instability, and host-tumor interactions provides valuable insights into the mechanisms underlying omental cancer. This knowledge is essential for the development of effective prevention strategies, diagnostic tools, and therapeutic interventions aimed at improving outcomes for patients affected by this challenging malignancy. Omental cancer presents significant challenges in both diagnosis and treatment, primarily due to its association with advanced-stage malignancies and the complexities inherent to its biology.

Conclusion

The interplay of metastatic pathways, microenvironmental factors, chronic inflammation, and genetic alterations all contribute to the pathogenesis of omental tumors, making them a critical focus for ongoing research. Despite advancements in imaging and therapeutic approaches, early detection remains elusive, often leading to poor prognosis for patients [7]. Current treatment strategies, which include surgical resection and systemic chemotherapy, need to be complemented by innovative therapeutic modalities such as targeted therapies and immunotherapy to enhance efficacy and improve survival rates. Research efforts aimed at understanding the molecular and cellular dynamics of omental cancer are essential for developing novel diagnostic biomarkers and effective treatment regimens. By unravelling the complex interactions within the tumor microenvironment and identifying potential therapeutic targets, we can aspire to provide better outcomes for individuals affected by this malignancy.

References

1. Haviland JS, Owen JR, Dewar JA, Agrawal RK, Barrett J, et al. (2013)The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol 14: 1086-1094.

Indexed at, Google Scholar, Crossref

2. Whelan T, MacKenzie R, Julian J, Levine M, Shelley W, et al. (2002)Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer. J Natl Cancer Inst 94: 1143-1150.

Indexed at, Google Scholar, Crossref

3. Whelan TJ, Pignol JP, Levine MN, Julian JA, MacKenzie R, et al. (2010)Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med 362: 513-520.

Indexed at, Google Scholar, Crossref

4. Wang SL, Fang H, Song YW, Wang WH, Hu C, et al. (2019)Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol 20: 352-360.

Indexed at, Google Scholar, Crossref

5. Sedlmayer F, Reitsamer R, Wenz F, Sperk E, Fussl C, et al. (2017)Intraoperative radiotherapy (IORT) as boost in breast cancer. Radiat Oncol 12: 1-7.

Indexed at, Google Scholar, Crossref

6. Fastner G, Reitsamer R, Urbański B, Kopp P, Murawa D, et al. (2020)Toxicity and cosmetic outcome after hypofractionated whole breast irradiation and boost-IOERT in early stage breast cancer (HIOB): first results of a prospective multicenter trial (NCT01343459). Radiother Oncol 146: 136-142.

Indexed at, Google Scholar, Crossref

7. Burgos-Burgos J, Vega V, Macias-Verde D, Gómez V, Travieso-Aja M, et al. (2021)Hypofractionated whole breast irradiation after IORT treatment: evaluation of acute toxicity and cosmesis. Clin Transl Oncol 23: 179-182.

Indexed at, Google Scholar, Crossref